The quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro and in vivo by targeting the hypoxia inducible factor-1 pathway

scientific article published on 24 January 2014

The quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro and in vivo by targeting the hypoxia inducible factor-1 pathway is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1002123350
P356DOI10.1186/1476-4598-13-12
P8608Fatcat IDrelease_q4pjdlmy2vhvpbtntlroai6h2q
P932PMC publication ID3932516
P698PubMed publication ID24461075
P5875ResearchGate publication ID259915920

P50authorHala Gali-MuhtasibQ51113283
Kazem ZibaraQ55293505
P2093author name stringMarwan El-Sabban
Makhluf J Haddadin
Hala Gali-Muhtasib
Sally El-Sitt
Khaled Ghattass
Saide Rayes
P2860cites workDirect regulation of TWIST by HIF-1alpha promotes metastasisQ24316939
Targeting HIF-1 for cancer therapyQ27860504
Metastasis: a question of life or deathQ28242176
Differentiation arrest by hypoxiaQ42797711
Quinoxaline 1,4-dioxides are novel angiogenesis inhibitors that potentiate antitumor effects of ionizing radiation.Q44832487
Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).Q45206507
Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancerQ46944975
Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularityQ59617803
Growth-related changes of oxygen consumption rates of tumor cells grown in vitro and in vivoQ69936647
Exploiting tumour hypoxia in cancer treatmentQ28264146
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology GroupQ28282755
Targeting hypoxia in cancer therapyQ29615491
Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasionQ33630843
Suppression of Hypoxia-Inducible Factor 1α (HIF-1α) by Tirapazamine Is Dependent on eIF2α Phosphorylation Rather Than the mTORC1/4E-BP1 PathwayQ33749777
HIF-1 and mechanisms of hypoxia sensingQ34180645
Conversion of stationary to invasive tumor initiating cells (TICs): role of hypoxia in membrane type 1-matrix metalloproteinase (MT1-MMP) traffickingQ34297111
The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasisQ34479984
Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimusQ34532986
Rapid non-genomic signalling by 17β-oestradiol through c-Src involves mTOR-dependent expression of HIF-1α in breast cancer cellsQ35263224
Radiosensitization by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide under oxia and hypoxia in human colon cancer cellsQ35589210
Gene expression and hypoxia in breast cancerQ35614451
Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasisQ36220525
Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancerQ36393103
Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent.Q36502589
DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX.Q36732878
Hypoxia-driven selection of the metastatic phenotypeQ36801461
Hypoxia and metastasis in breast cancer.Q36808477
Bioreductive drugs: from concept to clinicQ36812319
Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradationQ36994805
The tumor microenvironment and metastatic diseaseQ37187529
The radiosensitizer 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide induces DNA damage in EMT-6 mammary carcinoma cellsQ37276709
Targeting tumour hypoxia in breast cancerQ37319813
Cancer stem cells, hypoxia and metastasisQ37403294
Cancer stem cells at the crossroads of current cancer therapy failures--radiation oncology perspectiveQ37706840
Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010).Q37826426
Targeting hypoxia for sensitization of tumors to radio- and chemotherapyQ38107961
Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomicsQ38318356
Inhibition of angiogenesis and invasion by DMBT is mediated by downregulation of VEGF and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cellsQ39186478
The novel hypoxic cytotoxin, TX-2098 has antitumor effect in pancreatic cancer; possible mechanism through inhibiting VEGF and hypoxia inducible factor-1α targeted gene expressionQ39369979
Cell death by the quinoxaline dioxide DCQ in human colon cancer cells is enhanced under hypoxia and is independent of p53 and p21Q39631718
The novel hypoxic cell radiosensitizer, TX-1877 has antitumor activity through suppression of angiogenesis and inhibits liver metastasis on xenograft model of pancreatic cancerQ39944749
Inhibition of proliferation and induction of apoptosis by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide in adult T-cell leukemia cellsQ40531329
Quinoxaline 1,4-dioxides: hypoxia-selective therapeutic agentsQ40740278
Quinoxaline 1,4-dioxides as anticancer and hypoxia-selective drugs.Q40813759
Multidrug resistance in breast cancer: from in vitro models to clinical studiesQ42695791
P921main subjecthypoxiaQ105688
cancer metastasisQ120912394
P304page(s)12
P577publication date2014-01-24
P1433published inMolecular CancerQ15724585
P1476titleThe quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro and in vivo by targeting the hypoxia inducible factor-1 pathway
P478volume13

Reverse relations

cites work (P2860)
Q38944439Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines.
Q93358186Effects of VEGFR1+ hematopoietic progenitor cells on pre-metastatic niche formation and in vivo metastasis of breast cancer cells
Q64941626Genotoxic risk of quinocetone and its possible mechanism in in vitro studies.
Q36026944Hypoxia-induced carbonic anhydrase IX facilitates lactate flux in human breast cancer cells by non-catalytic function
Q28084024Mechanisms involved in breast cancer liver metastasis
Q47106685Mechanisms underlying the antiproliferative effects of a series of quinoxaline-derived chalcones
Q91671487Metastasis pattern and prognosis of male breast cancer patients in US: a population-based study from SEER database
Q55353906Organotropism: new insights into molecular mechanisms of breast cancer metastasis.
Q26752388Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of Actions
Q47938041Synthesis and Evaluation of New Quinoxaline Derivatives of Dehydroabietic Acid as Potential Antitumor Agents
Q92945770Synthesis and Properties of Quinoxaline-Containing Benzoxazines and Polybenzoxazines
Q38759912The photoprotective effects of 2-benzoyl-3-phenylquinoxaline 1,4-dioxide against UVB-induced damage in HaCaT cells
Q59801804Vandetanib (ZD6474) induces antiangiogenesis through mTOR–HIF-1 alpha–VEGF signaling axis in breast cancer cells

Search more.